# Salvage Therapy With Idarubicin in Relapsing CNS Lymphoma

> **NCT00210366** · PHASE2 · TERMINATED · sponsor: **International Extranodal Lymphoma Study Group (IELSG)** · enrollment: 25 (estimated)

## Conditions studied

- Lymphoma, B-Cell

## Interventions

- **DRUG:** Idarubicin

## Key facts

- **NCT ID:** NCT00210366
- **Lead sponsor:** International Extranodal Lymphoma Study Group (IELSG)
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2004-11
- **Primary completion:** 2010-07
- **Final completion:** —
- **Target enrollment:** 25 (ESTIMATED)
- **Why stopped:** due to slow accrual
- **Last updated:** 2010-07-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00210366

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00210366, "Salvage Therapy With Idarubicin in Relapsing CNS Lymphoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00210366. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*